Market cap
$3 Mln
Revenue (TTM)
$5 Mln
P/E Ratio
--
P/B Ratio
0.6
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -20.08 | -94.17 | -31.32 | 76.30 | 58.22 |
| EBIT | 25.44 | 49.92 | 30.56 | -191.58 | -197.98 |
| Net Profit | 32.94 | 71.56 | 73.74 | 0.87 | 5.20 |
| EPS | -- | -- | -- | -- | -- |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-21 | Dec-20 |
| EBIT-Margin
| -15,746.11 | -9,811.24 | -880.54 | -496.95 | -44,229.75 |
| Net Margin
| -92.92 | -255.76 | -52.30 | -1,977.58 | 1,149.10 |
| Return on equity
| -367.73 | -248.74 | -44.42 | -182.82 | -270.13 |
| Return on Capital
| -194.41 | -136.91 | -- | -173.29 | -156.29 |
| Return on Assets
| -107.75 | -77.25 | -21.83 | -110.01 | -71.98 |
| Debt to Equity (x)
| -- | -- | 0.00 | -- | 0.33 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
PLx Pharma (PLXP)
|
--
|
-173.29
|
-156.29
|
-253.66
|
7.12
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-44.42
Lower than Peers by 63.39
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
PLx Pharma (PLXP)
|
-44.42
|
-182.82
|
-270.13
|
-650.23
|
16.21
|
|
Peer Median
|
18.97
|
--
|
--
|
--
|
--
|
ROA
-21.83
Lower than Peers by 24.68
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
PLx Pharma (PLXP)
|
-21.83
|
-110.01
|
-71.98
|
-141.25
|
3.80
|
|
Peer Median
|
2.86
|
--
|
--
|
--
|
--
|
EBIT Margin
-880.54
Lower than Peers by 896.36
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
PLx Pharma (PLXP)
|
-880.54
|
-496.95
|
-44,229.75
|
-2,511.62
|
271.18
|
|
Peer Median
|
15.82
|
--
|
--
|
--
|
--
|
Net Margin
-52.30
Lower than Peers by 60.54
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
PLx Pharma (PLXP)
|
-52.30
|
-1,977.58
|
1,149.10
|
549.71
|
6.52
|
|
Peer Median
|
8.23
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
PLx Pharma (PLXP)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
-31.32
Lower than Peers by 39.37
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
PLx Pharma (PLXP)
|
-31.32
|
268.73
|
-0.95
|
-0.25
|
-0.03
|
|
Peer Median
|
8.05
|
--
|
--
|
--
|
--
|
EBIT Growth
30.56
Higher than Peers by 22.29
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
PLx Pharma (PLXP)
|
30.56
|
-203.07
|
5.23
|
-795.43
|
112.55
|
|
Peer Median
|
8.26
|
--
|
--
|
--
|
--
|
Net Profit Growth
73.74
Higher than Peers by 66.01
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
PLx Pharma (PLXP)
|
73.74
|
-249.76
|
37.67
|
-3,006.31
|
105.84
|
|
Peer Median
|
7.73
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
PLx Pharma (PLXP)
|
--
|
--
|
0.33
|
3.40
|
1.12
|
|
Peer Median
|
0.59
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
PLx Pharma (PLXP)
|
--
|
0.25
|
0.06
|
2.33
|
0.45
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
4.79
Higher than Peers by 3.14
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
PLx Pharma (PLXP)
|
4.79
|
6.19
|
6.49
|
2.34
|
3.14
|
|
Peer Median
|
1.65
|
--
|
--
|
--
|
--
|
Quick Ratio
4.28
Higher than Peers by 3.08
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
PLx Pharma (PLXP)
|
4.28
|
5.98
|
6.45
|
--
|
3.14
|
|
Peer Median
|
1.20
|
--
|
--
|
--
|
--
|
Interest Coverage
-171.58
Lower than Peers by 176.35
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
PLx Pharma (PLXP)
|
-171.58
|
-7.65
|
-43.71
|
-14.27
|
1.78
|
|
Peer Median
|
4.77
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
3.06
Lower than Peers by 18.21
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
PLx Pharma (PLXP)
|
3.06
|
7.72
|
--
|
3.30
|
2.42
|
|
Peer Median
|
21.27
|
--
|
--
|
--
|
--
|
Asset Turnover
0.07
Lower than Peers by 0.33
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
PLx Pharma (PLXP)
|
0.07
|
0.16
|
0.00
|
0.03
|
0.03
|
|
Peer Median
|
0.40
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
PLx Pharma (PLXP)
|
--
|
14.11
|
112.13
|
11.92
|
9.12
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
PLx Pharma (PLXP)
|
--
|
98.87
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
PLx Pharma (PLXP)
|
--
|
435.66
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
PLx Pharma (PLXP)
|
--
|
-322.68
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Book Value
0.58
Lower than Peers by 7.17
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
PLx Pharma (PLXP)
|
0.58
|
--
|
--
|
--
|
--
|
|
Peer Median
|
7.75
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
PLx Pharma (PLXP)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.50
|
--
|
--
|
--
|
--
|
EV/EBITDA
-0.09
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
PLx Pharma (PLXP)
|
-0.09
|
1.97
|
1.46
|
0.63
|
-3.15
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
3
Lower than Peers by 2,588
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
PLx Pharma (PLXP)
|
3
|
--
|
--
|
--
|
--
|
|
Peer Median
|
2,591
|
--
|
--
|
--
|
--
|